|
Age (years)
|
66.3±9.5 |
61.0±13.7 |
0.125 |
|
Sex (male/female)
|
18/5 |
21/7 |
0.686 |
|
Body mass index (kg/m2)
|
|
|
|
| <18.5 |
0 |
0 |
/ |
| 18.5–24.9 |
6 (26%) |
14 (50%) |
0.087 |
| 25–29.9 |
11 (48%) |
7 (25%) |
0.095 |
| 30–34.9 |
4 (17%) |
3 (11%) |
0.505 |
| 35–39.9 |
1 (4.5%) |
2 (7%) |
0.693 |
| ≥40 |
1 (4.5%) |
2 (7%) |
0.693 |
|
Pre-existing illness
|
|
|
|
| Coronary Heart Disease |
14 (60.9%) |
18 (64.3%) |
0.812 |
| Myocardial infarction |
6 (26.1%) |
7 (25%) |
0.940 |
| Cardiac valvulopathy |
11 (47.8%) |
10 (35.7%) |
0.393 |
| Heart failure |
8 (34.8%) |
7 (25%) |
0.457 |
| Diabetes mellitus |
11 (47.8%) |
15 (53.6%) |
0.694 |
| Smoking |
6 (26.1%) |
10 (35.7%) |
0.473 |
| COPD |
1 (4.4%) |
5 (17.9%) |
0.145 |
| Pulmonary emphysema |
1 (4.4%) |
2 (7.1%) |
0.693 |
| Chronic kidney disease |
2 (8.7%) |
5 (17.9%) |
0.357 |
| Liver disease |
0 (0%) |
1 (3.6%) |
0.386 |
|
Major preoperative diagnosis
|
|
|
|
| Pulmonary embolism + eCPR |
3 (13%) |
2 (7%) |
0.497 |
| TAVR + eCPR |
1 (4.4%) |
1 (3.6%) |
0.910 |
| PCI + eCPR |
3 (13%) |
5 (17.8%) |
0.265 |
|
Cardiac decompensation due
|
|
|
|
| to aortic valve stenosis III° |
4 (17%) |
2 (7%) |
0.270 |
| to aortic valve insufficiency III° |
2 (8.7%) |
1 (3.6%) |
0.457 |
| to tricuspid valve insufficiency III° |
1 (4.4%) |
0 |
0.287 |
| to mitral valve stenosis III° |
1 (4.4%) |
0 |
0.287 |
| to mitral valve insufficiency III° |
1 (4.4%) |
1 (3.6%) |
0.910 |
| to STEMI |
3 (13%) |
9 (32%) |
0.116 |
| to STEMI + ventricle rupture |
1 (4.4%) |
2 (7%) |
0.693 |
| Aortic root abscess |
1 (4.4%) |
0 |
0.287 |
| Type A aortic dissection |
0 |
4 (14%) |
0.064 |
| Endocarditis |
1 (4.4%) |
5 (17.9%) |
0.145 |
| Others |
1 (4.4%) |
1 (3.6%) |
0.910 |
|
Operation
|
|
|
|
| None |
9 (39%) |
9 (32%) |
0.797 |
| CABG |
5 (21.7%) |
2 (7.1%) |
0.140 |
| Valve surgical procedures |
2 (8.7%) |
5 (17.9%) |
0.357 |
| Combination (CABG + valve) |
7 (30.4%) |
12 (42.9%) |
0.372 |
|
Length of ICU stay (days)
|
23.0±35.5 |
13.5±14.8 |
0.670 |
|
VA-ECLS therapy (hours)
|
103.2±94.1 |
187.3±165.5 |
0.094 |
|
VA-ECLS implantation
|
|
|
|
| CPB weaning failure after surgery |
3 (13.0%) |
10 (35.7%) |
0.069 |
| postoperative |
13 (56.5%) |
10 (35.7%) |
0.144 |
| eCPR |
7 (30.4%) |
8 (28.5%) |
0.895 |
|
VA-ECLS cannulation
|
|
|
|
| central |
11 (47.8%) |
17 (60.7%) |
0.368 |
| peripheral |
12 (52.2%) |
11 (39.3%) |
0.368 |
|
Vasopressors
|
|
|
|
| Norepinephrine |
23 (100%) |
28 (100%) |
1.000 |
| Epinephrine |
13 (56.5%) |
27 (96.4%) |
< 0.001 |
| Dobutamine |
16 (69.5%) |
22 (78.5%) |
0.475 |
| Milrinone |
12 (52.2%) |
12 (42.8%) |
0.518 |
| Vasopressin |
8 (34.7%) |
5 (17.8%) |
0.176 |
| Levosimendan |
11 (47.8%) |
16 (57.1%) |
0.518 |
|
Organ replacement/support
|
|
|
|
| Impella |
0 (0%) |
3 (10.7%) |
0.114 |
| IABP |
4 (17.3%) |
7 (25.0%) |
0.524 |
| CRRT |
15 (65.2%) |
24 (85.7%) |
0.092 |
|
Transfusion
|
|
|
|
| Red blood cell concentrates |
26.6±29.6 |
29.4±36.6 |
0.007 |
| Fresh frozen plasma |
22.5±27.5 |
27.3±31.8 |
0.005 |
| Thrombocytes concentrates |
7.1±12.3 |
12.2±12.4 |
0.009 |
|
Complications
|
|
|
|
| Rethoracotomy |
7 (30.4%) |
11 (39.3%) |
0.522 |
| Manual CPR |
4 (17.4%) |
6 (21.4%) |
0.731 |
| Intracerebral hemorrhage |
1 (4.4%) |
4 (14%) |
0.247 |
| Stroke |
1 (4.4%) |
4 (14%) |
0.247 |
| Limb amputation |
2 (8.8%) |
1 (3.6%) |
0.457 |
| Hemolysis |
5 (21.7%) |
10 (35.7%) |
0.286 |
